Omnicell reported second quarter 2026 total revenues of $312 million, a 7% increase year-over-year. GAAP net income rose to $24 million ($0.52 per diluted share) from $6 million in the prior year period, while non-GAAP net income reached $44 million ($0.94 per diluted share). The company received $15 million in refunds for previously paid IEEPA tariffs. Omnicell updated its full year 2026 guidance, raising non-GAAP EBITDA to a range of $175 million-$185 million and non-GAAP EPS to $2.15-$2.30. The firm also announced the promotion of Nnamdi Njoku to President and Chief Operating Officer. Omnicell operates in the healthcare technology industry, providing autonomous medication management solutions.

Omnicell, Inc. appointed Nnamdi Njoku as President, effective July 1, 2026. Mr. Njoku will concurrently serve as Chief Operating Officer, reporting to Randall A. Lipps. Following this promotion, Mr. Lipps stepped down from the role of President but will continue as Chief Executive Officer and Chairman of the Board. As part of the appointment, the Compensation Committee approved a one-time equity award for Mr. Njoku with a target value of approximately $500,000 in restricted stock units. Mr. Njoku's 2026 annual base salary remains $661,000. Omnicell, Inc. is a healthcare technology company providing pharmacy automation and medication management solutions.